Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2.
Acute pulmonary injury is known as acute chest syndrome (ACS) in patients with sickle cell disease (SCD). Secretory phospholipase A2 (sPLA2) was found to predict those at risk for ACS and a trial was designed to determine if red blood cell transfusion can be used to prevent ACS. Patients with an elevated sPLA2 were randomised to either receive a single transfusion or standard care. Five of the eight patients (63%) randomised to standard care developed ACS versus none of the seven patients randomised to the transfusion arm (P = 0.026, Odds ratio = 23.6, 95% confidence interval 1, 557). This study suggests that transfusion may prevent ACS.
Styles
Lori A
LA
Department of Hematology/Oncology, Children's Hospital and Research Center at Oakland, Oakland, CA 94609, USA. lstyles@mail.cho.org
Abboud
Miguel
M
Larkin
Sandra
S
Lo
Margaret
M
Kuypers
Frans A
FA
D000208:Acute Disease; D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000150:complications / Q000201:enzymology / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D002637:Chest Pain / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D017707:Erythrocyte Transfusion; D005260:Female; D054501:Group II Phospholipases A2; D006801:Humans; D008297:Male; D010741:Phospholipases A / Q000097:blood*; D054467:Phospholipases A2; D012120:Respiration Disorders / Q000209:etiology / Q000517:prevention & control*; D014652:Vascular Diseases / Q000150:complications / Q000201:enzymology / Q000628:therapy
D015415:Biomarkers; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2